QRG Capital Management Inc. Buys 211,855 Shares of Boston Scientific Corporation $BSX

Key Points

• QRG Capital Management increased its Boston Scientific stake by 129.4% in the second quarter, purchasing 211,855 additional shares and bringing its holdings to 375,620 shares valued at approximately $16.0 million.
• Boston Scientific insiders also bought shares, including CEO Michael Mahoney’s purchase of 186,240 shares for roughly $9.0 million. Overall, insiders acquired 194,522 shares worth $9.4 million over the past 90 days.
• Despite the stock opening at $44.58 and trading near its 52-week low, Boston Scientific beat quarterly earnings and revenue estimates. Analysts maintain a “Moderate Buy” consensus with an average price target of $70.19.

QRG Capital Management Inc. lifted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 129.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 375,620 shares of the medical equipment provider's stock after acquiring an additional 211,855 shares during the period. QRG Capital Management Inc.'s holdings in Boston Scientific were worth $16,031,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. South Plains Financial Inc. purchased a new stake in shares of Boston Scientific during the fourth quarter valued at about $39,000. Clal Insurance Enterprises Holdings Ltd purchased a new position in shares of Boston Scientific in the 1st quarter worth approximately $28,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Boston Scientific in the 1st quarter worth approximately $32,000. Measured Wealth Private Client Group LLC raised its stake in shares of Boston Scientific by 244.9% during the 1st quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider's stock worth $34,000 after acquiring an additional 387 shares in the last quarter. Finally, Murphy & Mullick Capital Management Corp lifted its position in Boston Scientific by 121.6% during the fourth quarter. Murphy & Mullick Capital Management Corp now owns 565 shares of the medical equipment provider's stock valued at $54,000 after acquiring an additional 310 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael Mahoney acquired 186,240 shares of the company's stock in a transaction dated Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares of the company's stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director David Habiger acquired 2,100 shares of the business's stock in a transaction dated Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director directly owned 17,160 shares of the company's stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders acquired 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company's stock.

Boston Scientific Stock Down 0.8%

Boston Scientific stock opened at $44.58 on Thursday. The business's 50-day simple moving average is $46.96 and its two-hundred day simple moving average is $52.81. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The company has a market cap of $64.61 billion, a PE ratio of 18.05, a PEG ratio of 1.07 and a beta of 0.57. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $105.65.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company's revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 3.27 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on BSX. Evercore set a $65.00 price target on shares of Boston Scientific in a report on Monday, July 6th. Robert W. Baird set a $56.00 price objective on Boston Scientific in a research report on Thursday, July 30th. UBS Group dropped their target price on Boston Scientific from $74.00 to $67.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a research note on Thursday, May 28th. Finally, Needham & Company LLC lowered their price target on Boston Scientific from $77.00 to $57.00 and set a "buy" rating for the company in a report on Wednesday, July 8th. Twenty-three analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Boston Scientific has an average rating of "Moderate Buy" and an average price target of $70.19.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.